In light of the evidence provided by our study, it may be of particular interest to investigate the impact of BRCA1- and BRCA2-deficiency, separately, on the PD-L1 and PD-1 expression and the immune landscape in ovarian cancers as these studies considered BRCA1- and BRCA2-deficient ovarian cancers as a single entity [48, 49]. This evidence concerns the gene BRCA2 and ovarian carcinoma.